CAEL-101 is a Monoclonal Antibody owned by Alexion Pharmaceuticals, and is involved in 4 clinical trials, of which 1 was completed, and 3 are ongoing.

CAEL-101 acts by binding to amyloid related, conformational epitope on light chain related fibrils. This inhibits fibrillogenesis, induces an fragment crystallizable (Fc) mediated cellular inflammatory response, increases degradation and elimination of AL amyloidomas. It also prevents systemic light chain associated amyloid deposits and helps in treating relapsed or refractory amyloidosis.

The revenue for CAEL-101 is expected to reach a total of $1.4bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the CAEL-101 NPV Report.

CAEL-101 was originated by University of Tennessee Graduate School of Medicine and is currently owned by Alexion Pharmaceuticals. AstraZeneca is the other company associated in development or marketing of CAEL-101.

CAEL-101 Overview

CAEL-101 is under development for the treatment of relapsed or refractory amyloid light chain (AL) amyloidosis. The therapeutic candidate is administered as intravenous infusion. It is chimerized 11-F4 MAb (a murine amyloid-reactive monoclonal antibody, IgG1k) that acts by targeting amyloid related, conformational epitope on light chain (LC) related fibrils.

AstraZeneca Overview

AstraZeneca is a biopharmaceutical company, which is focused on discovery, production and commercialization of a range of prescription drugs. It develops products related to therapy areas such as respiratory, cardiovascular, renal and metabolic diseases, cancer, autoimmune, infection and neurological diseases. The company’s product portfolio includes biologics, prescription pharmaceuticals and vaccines. AstraZeneca sells its products through wholly-owned local marketing companies, distributors and local representative offices. The company markets its products to primary care and specialty care physicians. The COVID-19 Vaccine AstraZeneca has been approved for conditional marketing or emergency use. The company operates in Europe, the Americas, Asia, Africa and Australasia. AstraZeneca is headquartered in Cambridge, Cambridgeshire, the UK.

The company reported revenues of (US Dollars) US$37,417 million for the fiscal year ended December 2021 (FY2021), an increase of 40.6% over FY2020. In FY2021, the company’s operating margin was 2.8%, compared to an operating margin of 19.4% in FY2020. In FY2021, the company recorded a net margin of 0.3%, compared to a net margin of 12% in FY2020. The company reported revenues of US$10,982 million for the third quarter ended September 2022, an increase of 2% over the previous quarter.

Quick View – CAEL-101

Report Segments
  • Innovator
Drug Name
  • CAEL-101
Administration Pathway
  • Intravenous
Therapeutic Areas
  • Metabolic Disorders
Key Companies
Highest Development Stage
  • Phase III

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.